Format

Send to

Choose Destination
Biomed Rep. 2018 Apr;8(4):314-318. doi: 10.3892/br.2018.1067. Epub 2018 Feb 16.

Clinical applications of mesenchymal stem cells in chronic lung diseases.

Author information

1
Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion 71110, Crete, Greece.
2
Department of Thoracic Medicine, Interstitial Lung Disease Unit, University Hospital, University of Crete, Heraklion 71110, Crete, Greece.
3
Laboratory of Clinical Virology, Medical School, University of Crete, Voutes, Heraklion 71003, Crete, Greece.

Abstract

Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that have the ability to modulate immune response to tissue injury and promote repair in vivo. The therapeutic potential of ex vivo expanded MSCs are currently under investigation for a variety of chronic and acute lung diseases. This review summarizes the encouraging results regarding the safety of MSCs administration from recent and current clinical trials for idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and chronic obstructive pulmonary disease. It also reviews the early preliminary data extracted by the same trials regarding the efficacy of MSCs in the aforementioned lung diseases.

KEYWORDS:

acute respiratory distress syndrome; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; lung; mesenchymal stem cells

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center